Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity
暂无分享,去创建一个
E. Sausville | P. LoRusso | G. Schwartz | Yasuo Watanabe | S. Akinaga | M. Dickson | Y. Maekawa | Naomi Kashima | D. Nakashima